Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort. (PubMed, J Clin Med) - Oct 17, 2026 - "In second- and subsequent-line settings, PR rates were 25% with ibrutinib, 25% with extracorporeal photopheresis, 33.3% with ruxolitinib, and 20% with mesenchymal stem cell therapy, while no responses were observed with imatinib. Survival after BOS diagnosis was significantly longer in patients with a prior history of acute GVHD (79.7 vs. 25.7 months; p = 0.026) and in those with concomitant extrapulmonary cGVHD compared with isolated BOS (79.7 vs. 7.6 months; p = 0.001). Treatment responses in stage 2-3 BOS were limited, and survival remained very poor, highlighting the importance of earlier recognition and more effective therapies before fibrotic progression."
Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Transplantation
|
|
Ahmet Alparslan Ceran; Aysun Sar?er; Münevver ?rem Kök Y?lmaz; Nurdan Kokturk; Zübeyde Nur Özkurt; Özlem Güzel Tunçcan
|